Atlas Trials

Infections, Papillomavirus

65 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Infections, Papillomavirus

RecordFirmDate
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years (NCT02082639)GlaxoSmithKline2015-02-01
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study (NCT02100618)GlaxoSmithKline2015-01-01
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom (NCT01953822)GlaxoSmithKline2013-10-01
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK (NCT01905462)GlaxoSmithKline2012-11-01
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old (NCT01627561)GlaxoSmithKline2012-10-15
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study (NCT01418937)GlaxoSmithKline2012-05-29
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females (NCT01462357)GlaxoSmithKline2011-11-21
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada (NCT01290393)GlaxoSmithKline2011-09-26
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects (NCT01190176)GlaxoSmithKline2011-09-12
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls (NCT01381575)GlaxoSmithKline2011-06-29
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study (NCT01190189)GlaxoSmithKline2011-04-01
Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) (NCT01277042)GlaxoSmithKline2011-02-17
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study (NCT01249365)GlaxoSmithKline2011-01-24
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females (NCT01031069)GlaxoSmithKline2010-10-26
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination (NCT01153906)GlaxoSmithKline2010-10-01
Drug Use Investigation for Cervarix® (NCT01187927)GlaxoSmithKline2010-09-01
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females (NCT01101542)GlaxoSmithKline2010-07-01
Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway (NCT00924794)GlaxoSmithKline2010-06-01
Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia (NCT01213459)GlaxoSmithKline2010-04-01
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects (NCT00996125)GlaxoSmithKline2009-10-24
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects (NCT00947115)GlaxoSmithKline2009-09-22
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects (NCT00937950)GlaxoSmithKline2009-08-05
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study (NCT00929526)GlaxoSmithKline2009-06-01
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. (NCT00877877)GlaxoSmithKline2009-05-07
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. (NCT00811798)GlaxoSmithKline2009-05-01
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand (NCT00849381)GlaxoSmithKline2009-04-01
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US (NCT00799825)GlaxoSmithKline2009-01-01
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects (NCT00779766)GlaxoSmithKline2008-10-22
Cervarix Long-term Safety Surveillance (NCT01498627)GlaxoSmithKline2008-08-01
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects (NCT00652938)GlaxoSmithKline2008-04-09
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) (NCT00637195)GlaxoSmithKline2008-03-11
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females (NCT00586339)GlaxoSmithKline2008-01-17
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America (NCT00546078)GlaxoSmithKline2008-01-14
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects (NCT00578227)GlaxoSmithKline2007-12-15
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females (NCT00549900)GlaxoSmithKline2007-12-02
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age (NCT00552279)GlaxoSmithKline2007-11-12
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil (NCT00518336)GlaxoSmithKline2007-11-01
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs (NCT00541970)GlaxoSmithKline2007-10-17
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents (NCT00534638)GlaxoSmithKline2007-10-04
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer (NCT01207999)GlaxoSmithKline2007-10-01
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age (NCT00492544)GlaxoSmithKline2007-07-02
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years (NCT00485732)GlaxoSmithKline2007-06-11
Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A) (NCT00478621)GlaxoSmithKline2007-05-25
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years (NCT00456807)GlaxoSmithKline2007-04-01
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects (NCT00426361)GlaxoSmithKline2007-02-13
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age (NCT00423046)GlaxoSmithKline2007-01-24
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects (NCT00369824)GlaxoSmithKline2006-09-26
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years (NCT00345878)GlaxoSmithKline2006-09-25
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine (NCT00359619)GlaxoSmithKline2006-09-12
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women (NCT00344032)GlaxoSmithKline2006-07-28
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine (NCT00316693)GlaxoSmithKline2006-04-26
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. (NCT00309166)GlaxoSmithKline2006-04-05
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years (NCT00306241)GlaxoSmithKline2006-03-01
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older (NCT00294047)GlaxoSmithKline2006-02-16
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years (NCT00290277)GlaxoSmithKline2005-11-01
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. (NCT00250276)GlaxoSmithKline2005-10-28
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine. (NCT00231413)GlaxoSmithKline2005-03-04
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 (NCT00196937)GlaxoSmithKline2004-10-07
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 (NCT00169494)GlaxoSmithKline2004-09-01
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. (NCT00196924)GlaxoSmithKline2004-06-01
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 (NCT00122681)GlaxoSmithKline2004-05-06
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults (NCT00120848)GlaxoSmithKline2003-11-01
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women (NCT00689741)GlaxoSmithKline2001-01-01
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females (NCT00693615)GlaxoSmithKline2000-10-01

Track Infections, Papillomavirus automatically

Every clearance here is in the API, with alerts when new ones post.